Personal information

Other IDs

Scopus Author ID: 57189083436

Countries

United States

Activities

Collapse all

Employment (3)

University of Michigan: Ann Arbor, US

Employment
Source: check_circle
University of Michigan Symplectic Elements

VA Ann Arbor Healthcare System: Ann Arbor, MI, US

2021-03-01 to present | Investigator (Center for Clinical Management and Research)
Employment
Source: Self-asserted source
Garth Strohbehn

University of Michigan Rogel Cancer Center: Ann Arbor, MI, US

2021-03-01 to present | Assistant Professor
Employment
Source: Self-asserted source
Garth Strohbehn

Education and qualifications (5)

University of Chicago Comprehensive Cancer Center: Chicago, IL, US

2018-07 to 2021-02 | Fellow
Qualification
Source: Self-asserted source
Garth Strohbehn

University of Michigan Michigan Medicine: Ann Arbor, MI, US

2014-07 to 2018-07 | Resident, Chief Resident (Internal Medicine)
Qualification
Source: Self-asserted source
Garth Strohbehn

Yale University School of Medicine: New Haven, CT, US

2009 to 2014
Qualification
Source: Self-asserted source
Garth Strohbehn

University of Cambridge: Cambridge, Cambridgeshire, GB

2008 to 2009 | MPhil (Clinical Biochemistry)
Education
Source: Self-asserted source
Garth Strohbehn

University of Iowa: Iowa City, IA, US

2004 to 2008 | BA, BS
Education
Source: Self-asserted source
Garth Strohbehn

Works (50 of 117)

Items per page:
Page 1 of 3

Missed Opportunity for Sotorasib Dose Optimization

Journal of Clinical Oncology
2025-01-01 | Journal article
DOI: 10.1200/JCO-24-02468
SOURCE-WORK-ID:

2538818

PMID: 39913889
Part of ISSN: 0732-183X
Contributors: Garth Strohbehn; J Feldman; S Popat; M J Ratain
Source: check_circle
University of Michigan Symplectic Elements

Non-inferiority trials: tyranny or good governance? – Authors' reply

The Lancet Oncology
2025-01-01 | Journal article
DOI: 10.1016/S1470-2045(24)00717-4
SOURCE-WORK-ID:

2527463

PMID: 39756458
Part of ISSN: 1470-2045
Contributors: I F Tannock; M Buyse; M De Backer; H Earl; D A Goldstein; M J Ratain; L B Saltz; G S Sonke; Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study

The Lancet Oncology
2024-12-01 | Journal article
DOI: 10.1016/S1470-2045(24)00528-X
SOURCE-WORK-ID:

2505778

PMID: 39551068
Part of ISSN: 1470-2045
Contributors: S Miller; R Jiang; matthew schipper; Lars Fritsche; Garth Strohbehn; B Wallace; D Brinzevich; V Falvello; B H McMahon; R Zamora-Resendiz et al.
Source: check_circle
University of Michigan Symplectic Elements

Dosing and Schedule Questions: Connecting Health Services Research and Therapeutic Clinical Trials

2024-11-14 | Lecture
SOURCE-WORK-ID:

2502539
Contributors: Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System

Cancer Medicine
2024-11-01 | Journal article
DOI: 10.1002/cam4.70379
SOURCE-WORK-ID:

2498982

PMC: PMC11541111
PMID: 39508134
Part of ISSN: 2045-7634
Contributors: S R Miller; matthew schipper; Lars Fritsche; R Jiang; Garth Strohbehn; E Ötleş; B H McMahon; S Crivelli; R Zamora-Resendiz; N Ramnath et al.
Source: check_circle
University of Michigan Symplectic Elements

The tyranny of non-inferiority trials.

The Lancet Oncology
2024-10 | Journal article
DOI: 10.1016/S1470-2045(24)00218-3
SOURCE-WORK-ID:

2402169

PMID: 39362263
Part of ISSN: 1470-2045
Contributors: Ian F Tannock; Marc Buyse; Mickael De Backer; Helena Earl; Daniel A Goldstein; Mark J Ratain; Leonard B Saltz; Gabe S Sonke; Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Time and Financial Toxicity Implications during Consideration of Pembrolizumab Infusion Frequency

International Journal of Radiation Oncology Biology Physics
2024-10 | Conference paper
DOI: 10.1016/j.ijrobp.2024.07.1710
SOURCE-WORK-ID:

2486774

Part of ISSN: 0360-3016
Contributors: S Nori; Garth Strohbehn; Alex Bryant
Source: check_circle
University of Michigan Symplectic Elements

Toward post-approval dose optimization of cancer drugs

2024-09-06 | Lecture
SOURCE-WORK-ID:

2466034
Contributors: Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.

The Lancet Oncology
2024-06 | Journal article
DOI: 10.1016/S1470-2045(24)00200-6
SOURCE-WORK-ID:

2402178

PMID: 38821085
PMC: PMC11177338
Part of ISSN: 1470-2045
Contributors: Alex Bryant; Jacqueline R Lewy; R Daniel Bressler; Zoey Chopra; Derek J Gyori; Brian G Bazzell; Julie A Moeller; Sofia I Jacobson; Mark Fendrick; Eve A Kerr et al.
Source: check_circle
University of Michigan Symplectic Elements

Optimizing the doses of cancer drugs after usual dose finding

Clinical Trials
2024-06-01 | Journal article
DOI: 10.1177/17407745231213882
SOURCE-WORK-ID:

2351452

PMID: 38148731
Part of ISSN: 1740-7745
Contributors: Garth Strohbehn; W M Stadler; P S Boonstra; M J Ratain
Source: check_circle
University of Michigan Symplectic Elements

Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders

Nature Reviews Clinical Oncology
2024-05-01 | Journal article
DOI: 10.1038/s41571-024-00862-6
SOURCE-WORK-ID:

2363584

PMID: 38291134
Part of ISSN: 1759-4774
Contributors: Garth Strohbehn; M J Ratain
Source: check_circle
University of Michigan Symplectic Elements

‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent

Nature Reviews Clinical Oncology
2024-04-01 | Journal article
DOI: 10.1038/s41571-023-00857-9
SOURCE-WORK-ID:

2356779

PMID: 38182900
Part of ISSN: 1759-4774
Contributors: Garth Strohbehn; B Gyawali
Source: check_circle
University of Michigan Symplectic Elements

Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
2024-03-15 | Journal article
DOI: 10.1016/j.ijrobp.2023.09.050
SOURCE-WORK-ID:

2280223

PMID: 37793573
Part of ISSN: 0360-3016
Contributors: Donna Edwards; K Sankar; A Alseri; R Jiang; matthew schipper; S Miller; K Dess; Garth Strohbehn; D A Elliott; D Moghanaki et al.
Source: check_circle
University of Michigan Symplectic Elements

Special designations and the US Food and Drug Administration’s “dual mandate”

Journal of the National Cancer Institute
2024-02-01 | Journal article
DOI: 10.1093/jnci/djad235
SOURCE-WORK-ID:

2347886

PMID: 38062849
Part of ISSN: 0027-8874
Contributors: Garth Strohbehn; M J Ratain
Source: check_circle
University of Michigan Symplectic Elements

Immunotherapy in Prepatients - Preventing or Promoting a Malignant Transformation?

JAMA Oncology
2024-01-18 | Journal article
DOI: 10.1001/jamaoncol.2023.4799
SOURCE-WORK-ID:

2341000

PMID: 37971752
Part of ISSN: 2374-2437
Contributors: B Gyawali; Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?

European Journal of Cancer
2023-11 | Journal article
DOI: 10.1016/j.ejca.2023.113349
SOURCE-WORK-ID:

2281495

PMID: 37806256
Part of ISSN: 0959-8049
WOSUID:

WOS:001088938400001
Contributors: Mark J Ratain; Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Targeted randomization dose optimization trials enable fractional dosing of scarce drugs

PLoS ONE
2023-10-01 | Journal article
DOI: 10.1371/journal.pone.0287511
SOURCE-WORK-ID:

2314727

PMC: PMC10615276
PMID: 37903093
Part of ISSN: 1932-6203
Contributors: P S Boonstra; A Tabarrok; Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions

JCO Oncology Practice
2023-09-01 | Journal article
DOI: 10.1200/OP.23.00227
SOURCE-WORK-ID:

2249927

PMID: 37450776
PMC: PMC10538895
Part of ISSN: 2688-1527
Contributors: S I Jacobson; A J Kacew; R W Knoebel; P H Hsieh; M J Ratain; Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

Annals of Oncology
2023-08 | Journal article
DOI: 10.1016/j.annonc.2023.05.006
SOURCE-WORK-ID:

2225973

PMID: 37230253
Part of ISSN: 0923-7534
WOSUID:

WOS:001037829600001
Contributors: I F Tannock; G Bouche; D A Goldstein; Y Goto; A S Lichter; K Prabhash; P Ranganathan; L B Saltz; G S Sonke; Garth Strohbehn et al.
Source: check_circle
University of Michigan Symplectic Elements

Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions

Health Affairs
2023-07-01 | Journal article
DOI: 10.1377/hlthaff.2023.00102
SOURCE-WORK-ID:

2240598

PMC: PMC10985582
PMID: 37406228
Part of ISSN: 0278-2715
WOSUID:

WOS:001041569300008
Contributors: Alex Bryant; Z Chopra; Donna Edwards; A S Whalley; B G Bazzell; J A Moeller; M J Kelley; A Mark Fendrick; E A Kerr; N Ramnath et al.
Source: check_circle
University of Michigan Symplectic Elements

Alternative trastuzumab dosing schedules and association with health care greenhouse gas emissions.

Journal of Clinical Oncology
2023-06-01 | Conference paper
DOI: 10.1200/jco.2023.41.16_suppl.e13644
SOURCE-WORK-ID:

2285288

Part of ISSN: 0732-183X
Contributors: Garth Strohbehn; Sofia Jacobson; Alec Kacew; Randall W Knoebel; Po-Hung Hsieh; Mark J Ratain
Source: check_circle
University of Michigan Symplectic Elements

Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression

Clinical Lung Cancer
2023-05-01 | Journal article
DOI: 10.1016/j.cllc.2023.01.003
SOURCE-WORK-ID:

2146871

PMID: 36806414
Part of ISSN: 1525-7304
WOSUID:

WOS:000992429700001
Contributors: M C Tran; Garth Strohbehn; T G Karrison; S J Rouhani; J P Segal; A Shergill; P C Hoffman; J D Patel; M C Garassino; E E Vokes et al.
Source: check_circle
University of Michigan Symplectic Elements

New Strategies for Dose Optimization in Oncology: Insights From Targeted Small-Molecule Therapies for Metastatic or Advanced Non– Small Cell Lung Cancer

Clinical Advances in Hematology and Oncology
2023-04-01 | Other
SOURCE-WORK-ID:

2202218

PMID: 37039730
Part of ISSN: 1543-0790
WOSUID:

WOS:000969484500007
Contributors: Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2023-02-13 | Journal article | Author
DOI: 10.1200/jco.22.02049
PMID: 36780590
Contributors: Garth Strohbehn; Allen Lichter; Mark Ratain
Source: Self-asserted source
Garth Strohbehn
grade
Preferred source (of 2)‎

Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation

JAMA Oncology
2022 | Journal article
DOI: 10.1001/jamaoncol.2022.4109
EID:

2-s2.0-85139248643

Part of ISSN: 23742445 23742437
Contributors: Strohbehn, G.W.; Holleman, R.; Burns, J.; Klamerus, M.L.; Kelley, M.J.; Kerr, E.A.; Ramnath, N.; Hofer, T.P.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings

npj Breast Cancer
2022 | Journal article
DOI: 10.1038/s41523-022-00393-2
EID:

2-s2.0-85126207724

Part of ISSN: 23744677
Contributors: Hsieh, P.-H.; Kacew, A.J.; Dreyer, M.; Serritella, A.V.; Knoebel, R.W.; Strohbehn, G.W.; Ratain, M.J.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer

European Journal of Cancer
2022 | Journal article
DOI: 10.1016/j.ejca.2022.04.033
EID:

2-s2.0-85131748090

Part of ISSN: 18790852 09598049
Contributors: Bryant, A.K.; Sankar, K.; Zhao, L.; Strohbehn, G.W.; Elliott, D.; Moghanaki, D.; Kelley, M.J.; Ramnath, N.; Green, M.D.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Lorlatinib Exposed: A Far From Optimal Dose

Clinical Pharmacology and Therapeutics
2022 | Journal article
DOI: 10.1002/cpt.2579
EID:

2-s2.0-85127560576

Part of ISSN: 15326535 00099236
Contributors: Strohbehn, G.W.; Ratain, M.J.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan

Value in Health Regional Issues
2022 | Journal article
DOI: 10.1016/j.vhri.2022.01.007
EID:

2-s2.0-85127522686

Part of ISSN: 22121102 22121099
Contributors: Strohbehn, G.W.; Cooperrider, J.H.; Yang, D.; Fendrick, A.M.; Ratain, M.J.; Zaric, G.S.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab

International Journal of Radiation Oncology Biology Physics
2022 | Journal article
DOI: 10.1016/j.ijrobp.2022.03.015
EID:

2-s2.0-85128694902

Part of ISSN: 1879355X 03603016
Contributors: Bryant, A.K.; Sankar, K.; Strohbehn, G.W.; Zhao, L.; Daniel, V.; Elliott, D.; Ramnath, N.; Green, M.D.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Lung Cancer
2022 | Journal article
DOI: 10.1016/j.lungcan.2021.11.021
EID:

2-s2.0-85120736812

Part of ISSN: 18728332 01695002
Contributors: Bryant, A.K.; Sankar, K.; Strohbehn, G.W.; Zhao, L.; Elliott, D.; Qin, A.; Yentz, S.; Ramnath, N.; Green, M.D.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Provider-Level Barriers to Human Papillomavirus Vaccination in Survivors of Childhood and Young Adult Cancers

Journal of Adolescent and Young Adult Oncology
2022 | Journal article
DOI: 10.1089/jayao.2021.0096
EID:

2-s2.0-85131770857

Part of ISSN: 2156535X 21565333
Contributors: Kacew, A.J.; Jacobson, S.; Sheade, J.; Patel, A.A.; Hlubocky, F.J.; Lee, N.K.; Henderson, T.O.; Schneider, J.A.; Strohbehn, G.W.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
2022 | Journal article
DOI: 10.1016/j.ijrobp.2021.12.176
EID:

2-s2.0-85123846178

Part of ISSN: 1879355X 03603016
Contributors: Bryant, A.K.; Sankar, K.; Strohbehn, G.W.; Zhao, L.; Elliott, D.; Daniel, V.; Ramnath, N.; Green, M.D.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.

Expert opinion on pharmacotherapy
2022-10-20 | Journal article
DOI: 10.1080/14656566.2022.2134777
PMID: 36217844
Contributors: Strohbehn GW; Sankar K; Qin A; Kalemkerian GP
Source: Self-asserted source
Garth Strohbehn
grade
Preferred source (of 3)‎

Dose optimisation and scarce resource allocation: two sides of the same coin.

BMJ open
2022-10-12 | Journal article | Author
DOI: 10.1136/bmjopen-2022-063436
PMID: 36223969
PMC: PMC9562718
Contributors: Garth Strohbehn; Persad G; Parker WF; Murthy S
Source: Self-asserted source
Garth Strohbehn
grade
Preferred source (of 3)‎

Carbon emissions and non-biodegradable medical waste generation with alternative dosing strategies.

Journal of Clinical Oncology
2022-10-01 | Conference paper
DOI: 10.1200/jco.2022.40.28_suppl.044
SOURCE-WORK-ID:

2285289

Part of ISSN: 0732-183X
Contributors: Sofia I Jacobson; Alec Kacew; Randall W Knoebel; Po-Hung Hsieh; Mark J Ratain; Garth Strohbehn
Source: check_circle
University of Michigan Symplectic Elements

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer

Cancers
2022-01 | Journal article | Author
DOI: 10.3390/cancers14030614
Contributors: Kamya Sankar; Alex K. Bryant; Garth Strohbehn; Lili Zhao; David Elliott; Drew Moghanaki; Michael J. Kelley; Nithya Ramnath; Michael Green
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 3)‎

Artificial Intelligence Can Cut Costs While Maintaining Accuracy in Colorectal Cancer Genotyping

Frontiers in Oncology
2021 | Journal article
DOI: 10.3389/fonc.2021.630953
EID:

2-s2.0-85108335110

Part of ISSN: 2234943X
Contributors: Kacew, A.J.; Strohbehn, G.W.; Saulsberry, L.; Laiteerapong, N.; Cipriani, N.A.; Kather, J.N.; Pearson, A.T.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

As the Story Unfolds

Journal of hospital medicine
2021 | Journal article
DOI: 10.12788/jhm.3518
EID:

2-s2.0-85110323245

Part of ISSN: 15535606
Contributors: Strohbehn, G.W.; Saint, S.; Grinblatt, D.L.; Moe, J.; Dhaliwal, G.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Association between Administration of IL-6 Antagonists and Mortality among Patients Hospitalized for COVID-19: A Meta-analysis

JAMA - Journal of the American Medical Association
2021 | Journal article
DOI: 10.1001/jama.2021.11330
EID:

2-s2.0-85112256383

Part of ISSN: 15383598 00987484
Contributors: Shankar-Hari, M.; Vale, C.L.; Godolphin, P.J.; Fisher, D.; Higgins, J.P.T.; Spiga, F.; Savović, J.; Tierney, J.; Baron, G.; Benbenishty, J.S. et al.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Combination therapy patents: a new front in evergreening

Nature Biotechnology
2021 | Journal article
DOI: 10.1038/s41587-021-01137-6
EID:

2-s2.0-85121375476

Part of ISSN: 15461696 10870156
Contributors: Strohbehn, G.W.; Kacew, A.J.; Goldstein, D.A.; Feldman, R.C.; Ratain, M.J.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia

Clinical Pharmacology and Therapeutics
2021 | Journal article
DOI: 10.1002/cpt.2117
EID:

2-s2.0-85097385853

Part of ISSN: 15326535 00099236
Contributors: Strohbehn, G.W.; Heiss, B.L.; Rouhani, S.J.; Trujillo, J.A.; Yu, J.; Kacew, A.J.; Higgs, E.F.; Bloodworth, J.C.; Cabanov, A.; Wright, R.C. et al.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up

Arthritis and Rheumatology
2021 | Conference paper
SOURCE-WORK-ID:

1406907

Part of ISSN: 2326-5191
WOSUID:

WOS:000744545206119
Contributors: Lauren He; Garth Strohbehn; Pankti Reid
Source: check_circle
University of Michigan Symplectic Elements

Registration trials in countries without access to US standards of care — pitfalls of interpretation

Nature Reviews Clinical Oncology
2021 | Journal article
DOI: 10.1038/s41571-021-00506-z
EID:

2-s2.0-85104053090

Part of ISSN: 17594782 17594774
Contributors: Strohbehn, G.W.; Goldstein, D.A.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction

ResearchSquare
2021 | Other
DOI: 10.21203/rs.3.rs-1083825
EID:

2-s2.0-85131935470
Contributors: Gajewski, T.F.; Rouhani, S.J.; Trujillo, J.A.; Pyzer, A.R.; Yu, J.; Fessler, J.; Cabanov, A.; Higgs, E.F.; Cron, K.R.; Zha, Y. et al.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier

Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction

medRxiv
2021 | Other
DOI: 10.1101/2021.12.09.21266492
EID:

2-s2.0-85122553302
Contributors: Rouhani, S.J.; Trujillo, J.A.; Pyzer, A.R.; Yu, J.; Fessler, J.; Cabanov, A.; Higgs, E.F.; Cron, K.R.; Zha, Y.; Lu, Y. et al.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier

Socially optimal pandemic drug dosing

The Lancet Global Health
2021 | Journal article
DOI: 10.1016/S2214-109X(21)00251-5
EID:

2-s2.0-85110507667

Part of ISSN: 2214109X
Contributors: Strohbehn, G.W.; Parker, W.F.; Reid, P.D.; Gellad, W.F.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Teleoncology for Veterans: High Patient Satisfaction Coupled With Positive Financial and Environmental Impacts

JCO oncology practice
2021 | Journal article
DOI: 10.1200/OP.21.00317
EID:

2-s2.0-85116955049

Part of ISSN: 26881535
Contributors: Jiang, C.Y.; Strohbehn, G.W.; Dedinsky, R.M.; Raupp, S.M.; Pannecouk, B.M.; Yentz, S.E.; Ramnath, N.
Source: Self-asserted source
Garth Strohbehn via Scopus - Elsevier
grade
Preferred source (of 2)‎

Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction.

Res Sq
2021-11-24 | Other
DOI: 10.21203/rs.3.rs-1083825/v1
SOURCE-WORK-ID:

2285291

PMID: 34845442
PMC: PMC8629200
Part of ISSN: 2693-5015
Contributors: Sherin J Rouhani; Jonathan A Trujillo; Athalia R Pyzer; Jovian Yu; Jessica Fessler; Alexandra Cabanov; Emily F Higgs; Kyle R Cron; Yuanyuan Zha; Yihao Lu et al.
Source: check_circle
University of Michigan Symplectic Elements

P24.04 Concordance of Tissue and Cell-Free DNA-Based Next-Generation Sequencing in Patients With Lung Adenocarcinoma

Journal of Thoracic Oncology
2021-10 | Conference paper
DOI: 10.1016/j.jtho.2021.08.369
SOURCE-WORK-ID:

2285292

Part of ISSN: 1556-0864
Contributors: M Tran; Garth Strohbehn; S Rouhani; A Shergill; P Hoffman; J Patel; J Segal; E Vokes; C Bestvina
Source: check_circle
University of Michigan Symplectic Elements
Items per page:
Page 1 of 3

Peer review (3 reviews for 3 publications/grants)

Review activity for Contemporary clinical trials communications. (1)
Review activity for Journal of general internal medicine. (1)
Review activity for The Lancet regional health. (1)
How many people are using ORCID?